the new generation glocalized patient network in theragenomic and personalized medicine and individualized drug safety
January 26, 2021 –Â To date, a rare serious adverse (drug) reaction (SADR) has been noted to be associated with the first two Covid-19 vaccines, i.e., the one from Pfizer-BioNTech and the one from Moderna. We are talking about anaphylaxis, which …
Rare cases of anaphylaxis with COVID-19 vaccines Read more »
October 31, 2018 – The American Food and Drug Administration (FDA) Â recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for …
December 23, 2014 – The U.S. Food and Drug Administration (FDA) just approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use …
The weight-management drug Liraglutide (Saxenda) has just been approved by the FDA Read more »
March 19, 1014 – We just learned from a recent Press Release by the American Food and Drug Administration (FDA) on the approval of Metreleptin [Myalept] to treat leptin deficiency. Read the article below: On February 24, 2014, the U.S. …
FDA approves Metreleptin [Myalept] to treat rare metabolic disease Read more »
![FDA has approved Pertuzumab [Perjeta] in combination with Trastuzumab [Herceptin] and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer](https://thasso.com/wp-content/uploads/2012/06/Breast-Cancer-II-African-II.png)
June 11, 2012 – The American Food and Drug Administration (FDA) has approved Pertuzumab [Perjeta].  Pertuzumab [Perjeta] is approved in combination with Trastuzumab [Herceptin]  and docetaxel chemotherapy for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have …
June 12, 2012 — Two diagnostic tests to identify HER2-positive breast cancer have been approved by the US Food and Drug Administration (FDA) for use as companion diagnostics for the new targeted therapy Pertuzumab [Perjeta]. The tests — HercepTest and …
New Breast Cancer HER2 Diagnostic Tests Approved by FDA Read more »